Tumor Necrosis Factor TRIZ Cases
- Oncolytic Adenoviral Vectors for Adoptive Cell Tumor Trafficking
Oncolytic adenoviral vectors deliver cytokines into tumors to improve adoptive cell trafficking, persistence, and killing while limiting side effects.
- IL-1β/TNF-α Ratio Biomarker for Sepsis Prognosis Prediction
Using the IL-1β to TNF-α blood ratio improves early prognosis prediction in sepsis and helps identify candidates for IL-6 inhibitor treatment.
- Anti-CD100 VHH-Fc Antibody for Blocking CD100-Plexin Signaling
Single-domain anti-CD100 antibodies with Fc fusion improve CD100-Plexin blocking and inhibit MDSC proliferation for tumor control.
- Protein Marker Panels for Infection Severity Classification
Multiple host protein markers improve bacterial-versus-viral differentiation and infection severity assessment for better treatment decisions.
- Adoptive Cell Therapy With Oncolytic Adenoviral Cytokine Delivery
Oncolytic adenoviral vectors deliver cytokines locally to recruit and sustain transferred immune cells while limiting systemic toxicity.
- Allogeneic Tumor Cell Vaccine With Multi-Immunomodulator Expression
Engineered tumor cells express multiple immunomodulators to counter immune evasion, activate dendritic cells, and induce tumor-specific T-cell responses.
- XE114 Antibody Targeting CAIX for Solid Tumors
XE114 antibody binds carbonic anhydrase IX to enable targeted cancer diagnosis and therapy.
- Immune Cell Ratio Prediction for Anti-TNF Therapy Response
Measuring innate and adaptive immune cell ratios identifies responders to anti-TNF-alpha therapy, preventing disease progression from ineffective treatment.